Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam for Sedation in EBUS-TBNA (REST)
NCT06275594Phase 2Not yet recruiting
- Sponsor
- Yeungnam University Medical Center
- Start
- Mar 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of remimazolam in sedation (3 arms), sponsored by Yeungnam University Medical Center. Primary endpoint: Procedural success during EBUS-TBNA up to 1 hour. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
sedation
Beyond the preview
Go deeper on NCT06275594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06275594.